Cepton (CPTN)
(Delayed Data from NSDQ)
$2.90 USD
-0.10 (-3.34%)
Updated May 10, 2024 04:00 PM ET
After-Market: $2.90 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
F Value C Growth B Momentum F VGM
Price, Consensus and EPS Surprise
CPTN 2.90 -0.10(-3.34%)
Will CPTN be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for CPTN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CPTN
Luminar Technologies, Inc. (LAZR) Reports Q1 Loss, Misses Revenue Estimates
Lear (LEA) Q1 Earnings Beat Estimates
CPTN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Cepton, Inc. (CPTN) Reports Q4 Loss, Tops Revenue Estimates
Gentherm (THRM) Q4 Earnings and Revenues Top Estimates
Cepton, Inc. (CPTN) Reports Q2 Loss, Lags Revenue Estimates
Other News for CPTN
Cepton Unveils Proprietary End-to-End Lidar Simulator, StudioViz™
Cepton, Inc. Announces First Quarter 2024 Earnings Release and Conference Call Date
Next-Level Gains: 3 Stocks Poised to Crush the Digital Revolution
3 Unstoppable Stocks That Could Turn $500 into $50K by 2026
Hold Rating on Cepton Amidst Revenue Uncertainty and Loss of GM Orders